The Autopsy / Case File · Overdose & Substance
A Different Kind of Overdose
Fentanyl deaths fell hard in 2024, and the country called it progress. Deaths involving methamphetamine and cocaine fell too, but much more slowly — because naloxone, the drug that made the fentanyl decline possible, was never built to stop what a stimulant overdose actually does to a body.
CDC's National Center for Health Statistics recorded the age-adjusted rate of overdose deaths involving psychostimulants with abuse potential — a category dominated by methamphetamine — rising from 3.9 per 100,000 people in 2018 to 10.6 in 2023, a 172 percent increase, while cocaine-involved deaths rose from 4.5 to 8.6 per 100,000 over the same years. In 2024, as the overall U.S. overdose death rate fell 26.2 percent on the strength of a fentanyl-supply and naloxone-access decline, the psychostimulant death rate fell only 19.8 percent — a smaller drop, in a category with no equivalent reversal drug, because a stimulant overdose doesn't fail the way an opioid overdose fails. It doesn't shut down breathing. It attacks the heart, the brain's blood supply, and the body's ability to cool itself, three mechanisms naloxone has no effect on at all.
Join the discussion →
For most of the last decade, the national overdose story has had one main character: fentanyl, and the opioid-receptor mechanism that makes it lethal. A fentanyl overdose kills by shutting down the brainstem's drive to breathe — a slow, silent respiratory failure that naloxone can reverse in minutes if someone is there to give it, which is exactly why 2024's steep national overdose decline tracks so closely with the years naloxone distribution scaled up nationally. CDC's own data confirms the pattern held: total U.S. overdose deaths fell from 105,007 in 2023 to 79,384 in 2024, a 26.2 percent single-year drop, the largest on record. But methamphetamine and cocaine — the two drugs driving what toxicologists call the stimulant side of the overdose crisis — didn't fall at anywhere near that rate, and the reason isn't a policy failure or a supply-chain quirk. It's that the entire architecture built to reverse the fentanyl crisis, from take-home naloxone kits to opioid-focused bystander training, was never designed to touch a stimulant death in the first place.
A Line That Didn't Bend the Same Way
The numbers are stark on their own terms. NCHS Data Brief 549, covering 2023 through 2024, found the age-adjusted rate of drug overdose deaths involving psychostimulants with abuse potential — the CDC's formal category, which in practice is overwhelmingly methamphetamine — fell from 10.6 per 100,000 in 2023 to 8.5 in 2024, a 19.8 percent decline. That sounds like real progress, and in absolute terms it is. But set next to the 26.2 percent decline in the overall overdose rate over the same year, the gap is the story: stimulant deaths are being pulled down by the same tide lifting opioid deaths out of the crisis, not by anything that addresses methamphetamine or cocaine specifically. Zoom out further and the five years before that decline show the underlying trend more clearly. The psychostimulant death rate rose from 3.9 per 100,000 in 2018 to a peak of 10.6 in 2023 — closely tracked by a raw count of nearly 35,000 deaths that year alone, a number that would have been a historic, standalone national emergency in almost any other five-year period on record before fentanyl redefined the scale of the crisis.
Why Naloxone Doesn't Reach It
The mechanism gap is the part of this story that surveillance data alone can't fully convey, but it's the reason the two curves diverged. An opioid overdose is, physiologically, a single well-understood failure: opioids bind to receptors in the brainstem that control the automatic drive to breathe, and in high enough doses that drive slows, then stops, while the heart keeps beating for several more minutes on a body that is no longer getting oxygen. Naloxone works because it displaces the opioid from those receptors almost immediately, restoring the drive to breathe before the heart runs out of oxygen. It is, in a narrow but crucial sense, a single-mechanism antidote for a single-mechanism poison.
A stimulant overdose has no equivalent single point of failure, which is exactly why it has no equivalent single-point antidote. Clinical literature on stimulant toxicity describes an overdose that can present as a cardiovascular event — a sudden arrhythmia, a heart attack, a stroke triggered by a spike in blood pressure severe enough to rupture a vessel — or as a thermoregulatory collapse, in which methamphetamine's effect on the body's temperature-control system drives core temperature high enough to cause organ failure independent of any breathing problem at all, or as an acute psychiatric crisis severe enough to be lethal through resulting trauma or exhaustion. None of those three pathways involves the opioid receptors naloxone targets. A bystander who has been trained, correctly, to recognize an opioid overdose — slowed or absent breathing, blue lips, unresponsiveness that naloxone can reverse — is looking for a symptom picture that a pure stimulant overdose frequently does not produce until it is too late to intervene.
The entire bystander-response infrastructure built over the last decade — the naloxone kits, the training, the standing orders — was built to answer one specific way of dying. Methamphetamine doesn't die that way.
The Fentanyl Overlap That Complicates the Picture
The story isn't a clean split between "opioid deaths" and "stimulant deaths," and CDC surveillance covering January 2021 through June 2024 makes that overlap explicit. Across more than 309,000 overdose deaths in that window, 59.0 percent involved a stimulant of some kind, and of those, 73.0 percent also involved an opioid — almost always illicitly manufactured fentanyl, either intentionally combined by a supplier or unknowingly present in a stimulant supply the buyer didn't know was contaminated. Only 15.9 percent of all overdose deaths in the surveillance period involved a stimulant with no opioid present at all — meaning naloxone genuinely does help in a majority of stimulant-involved deaths, because most of them have a co-occurring opioid component that naloxone can address, buying time even when it can't touch the stimulant's own toxicity.
But that overlap cuts both ways, and the deaths without an opioid present are where the mechanism gap shows most starkly. CDC's analysis found that people who died with stimulants but no opioids in their system were older on average — 66.5 percent were 45 or older, compared with 44.2 percent among deaths that also involved opioids — and far more likely to have a documented history of cardiovascular disease: 38.7 percent, compared with 21.2 percent among opioid-involved stimulant deaths. That pattern is consistent with a population whose overdoses are being driven primarily by the cardiac mechanism directly, in bodies where a preexisting vulnerable heart had less margin to survive a stimulant-driven arrhythmia or hypertensive event, independent of any opioid-driven respiratory failure a rescuer might have been positioned to reverse.
Who the Rate Actually Moved For
The demographic pattern behind the national numbers points to a specific and largely under-discussed disparity. Among American Indian and Alaska Native people, the age-adjusted psychostimulant-involved death rate rose from 11.0 per 100,000 in 2018 to 32.9 in 2023 — nearly triple the increase of the national rate over the identical period, and by 2023 more than three times the overall national psychostimulant rate. Cocaine-involved deaths show a comparable racial concentration in a different population: among Black Americans specifically, the cocaine-involved death rate rose from 9.1 per 100,000 in 2018 to 24.3 in 2023, more than triple the national cocaine rate for the same year. Both patterns describe the same underlying dynamic from different angles — stimulant supplies contaminated with fentanyl reaching populations with long-standing, disproportionate cocaine or methamphetamine use, at a moment when the overdose-response infrastructure built around opioids was calibrated to a different population's drug of choice.
None of this is a case against naloxone, which remains the single most effective tool available against the opioid share of the crisis and the reason the national overdose count is falling at all. It's a case that the fentanyl decline, real as it is, has been mistaken in public understanding for a broader overdose-crisis decline it was never built to deliver. Methamphetamine and cocaine deaths are still climbing in raw terms across most of the last decade, they still kill through mechanisms no widely distributed reversal drug addresses, and the specific populations bearing the worst of that mechanism gap — older adults with cardiovascular disease, American Indian and Alaska Native communities, Black cocaine users exposed to a fentanyl-contaminated supply — are not the populations the last five years of overdose-response investment was built around.
And Then You're Dead
A body doesn't care which drug did it. It cares whether the heart holds, whether the vessel stays intact, whether the temperature stops climbing in time. Naloxone answers one of those questions. For a growing share of America's overdose dead, it was never the right question to begin with.
That's it. That's the whole thing.
Sources
- Age-adjusted psychostimulant-involved overdose death rates, 2023 (10.6 per 100,000) and 2024 (8.5 per 100,000), the 19.8% year-over-year decline, and the 26.2% overall overdose death rate decline (31.3 to 23.1 per 100,000; 105,007 to 79,384 total deaths) — "Drug Overdose Deaths in the United States, 2023–2024," NCHS Data Brief No. 549, National Center for Health Statistics, CDC
- 2018 psychostimulant rate (3.9 per 100,000) and cocaine rate (4.5 per 100,000) for trend comparison — "Drug Overdose Deaths in the United States, 2002–2022," NCHS Data Brief No. 491, CDC, March 2024
- Stimulant-involved overdose death polysubstance data (Jan 2021–June 2024): 59.0% of overdose deaths involved stimulants, 73.0% of those co-involved opioids, and age/cardiovascular-disease-history breakdowns for stimulant deaths with vs. without opioids present — "Drug Overdose Deaths Involving Stimulants — United States, January 2018–June 2024," CDC surveillance report, 2025
- 2023 race-stratified rates: American Indian/Alaska Native psychostimulant rate (11.0 in 2018 to 32.9 in 2023) and Black cocaine-involved death rate (9.1 in 2018 to 24.3 in 2023) — CDC NCHS drug overdose mortality surveillance, race/ethnicity-stratified data, 2018–2023
- Clinical mechanism of stimulant overdose (cardiovascular complications including stroke, thermoregulatory disruption, and acute psychiatric symptoms) as distinct from opioid-overdose respiratory depression — CDC Overdose Prevention, "Stimulant Overdose" clinical guidance
- Photo: "Crystal methamphetamine," WikiLinuz, CC0 1.0 Universal Public Domain Dedication, via Wikimedia Commons
Comments
Loading…